Condition: Breast Cancer · Sponsor: First Hospital of China Medical University
This multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the early warning model in guiding the targeted prevention of myocardial protection, providing an important theoretical basis for reducing the mortality rate of breast cancer and improving the prognosis.
This description comes directly from the study's public registry record.
Yonghuai Wang, Ph.D · +86 15998323056 · wyh_wyh2012@163.com
Always discuss trial participation with your own doctor first.
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Dalian Friendship Hospital | Dalian, Liaoning, China | Recruiting |
| Dalian Municipal Central Hospital | Dalian, Liaoning, China | Recruiting |
| Liaoning Cancer Hospital & Institute | Shenyang, Liaoning, China | Recruiting |
| The Third People's Hospital Of Chengdu | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06282796